Taken altogether, PD-L1 remains an imprecise marker for CPI response due to spatial and temporal heterogeneity within a specific tumor sample and across metastatic sites [143,144], lack of standardization in terms of quantification methods and selection of a threshold to define positivity, and variation between assays and antibody clones [145]. This evidence concerns the gene CD274 and neoplasm.